Literature DB >> 22444876

Design, synthesis and evaluation of isaindigotone derivatives as dual inhibitors for acetylcholinesterase and amyloid beta aggregation.

Jin-Wu Yan1, Yan-Ping Li, Wen-Jie Ye, Shuo-Bin Chen, Jin-Qiang Hou, Jia-Heng Tan, Tian-Miao Ou, Ding Li, Lian-Quan Gu, Zhi-Shu Huang.   

Abstract

A series of isaindigotone derivatives and analogues were designed, synthesized and evaluated as dual inhibitors of cholinesterases (ChEs) and self-induced β-amyloid (Aβ) aggregation. The synthetic compounds had IC(50) values at micro or nano molar range for cholinesterase inhibition, and some compounds exhibited strong inhibitory activity for AChE and high selectivity for AChE over BuChE, which were much better than the isaindigotone derivatives previously reported by our group. Most of these compounds showed higher self-induced Aβ aggregation inhibitory activity than a reference compound curcumin. The structure-activity relationship studies revealed that the derivatives with higher inhibition activity on AChE also showed higher selectivity for AChE over BuChE. Compound 6c exhibiting excellent inhibition for both AChE and self-induced Aβ aggregation was further studied using CD, EM, molecular docking and kinetics.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22444876     DOI: 10.1016/j.bmc.2012.02.061

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  7 in total

1.  2-Aryl-3-(arylideneamino)-1,2-dihydroquinazoline-4(3H)-ones as inhibitors of cholinesterases and self-induced β-amyloid (Aβ) aggregation: biological evaluations and mechanistic insights from molecular dynamics simulations.

Authors:  Sri Devi Sukumaran; Fadhil Lafta Faraj; Vannajan Sanghiran Lee; Rozana Othman; Michael J C Buckle
Journal:  RSC Adv       Date:  2018-02-19       Impact factor: 4.036

2.  Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer's disease.

Authors:  Suresh K Bowroju; Narsimha R Penthala; Naga Rajiv Lakkaniga; Meenakshisundaram Balasubramaniam; Srinivas Ayyadevara; Robert J Shmookler Reis; Peter A Crooks
Journal:  Bioorg Med Chem       Date:  2021-07-14       Impact factor: 3.461

Review 3.  Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease.

Authors:  Natalia Guzior; Anna Wieckowska; Dawid Panek; Barbara Malawska
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

4.  Virtual screening following rational drug design based approach for introducing new anti amyloid beta aggregation agent.

Authors:  Garshasb Rigi; Mohammad Vala Ashdar Nakhaei; Hoda Eidipour; Arshia Najimi; Fahimeh Tajik; Niloufar Taher; Kamran Yarahmadi
Journal:  Bioinformation       Date:  2017-02-28

5.  A Novel Isaindigotone Derivative Displays Better Anti-Proliferation Activities and Induces Apoptosis in Gastric Cancer Cells.

Authors:  Kangjia Du; Chengjie Yang; Zhongkun Zhou; Yunhao Ma; Yanan Tian; Rentao Zhang; Hao Zhang; Xinrong Jiang; Hongmei Zhu; Huanxiang Liu; Peng Chen; Yingqian Liu
Journal:  Int J Mol Sci       Date:  2022-07-21       Impact factor: 6.208

6.  Structure-based search for new inhibitors of cholinesterases.

Authors:  Marek Bajda; Anna Więckowska; Michalina Hebda; Natalia Guzior; Christoph A Sotriffer; Barbara Malawska
Journal:  Int J Mol Sci       Date:  2013-03-11       Impact factor: 5.923

7.  Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease.

Authors:  Angel Agis-Torres; Monica Sölhuber; Maria Fernandez; J M Sanchez-Montero
Journal:  Curr Neuropharmacol       Date:  2014-01       Impact factor: 7.363

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.